LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTMRG003 CLINICAL TRIAL RESULTS SELECTED ASLBA FOR ORAL PRESENTATION AT 2025 ASCO ANNUAL MEETING
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTUPDATE ON NEW DRUG APPLICATION OF MRG003
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
LEPU BIO-B: INSIDE INFORMATION ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR NOVEL ADC MRG007
LEPU BIO-B: CHANGE OF ADDRESSOF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
LEPU BIO-B: PROXY FORM FOR USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
LEPU BIO-B: ANNOUNCEMENT OFPROPOSED CHANGE OF AUDITOR
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTACCEPTANCE OF THE NEW DRUG APPLICATION AND PRIORITYREVIEW GRANTED BY NMPA TOMRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
LEPU BIO-B: ARTICLES OF ASSOCIATION
LEPU BIO-B: AMENDMENTS TO THE ARTICLES OF ASSOCIATION
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTBREAKTHROUGH THERAPY DESIGNATION GRANTEDBY THE FDA TO MRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024